Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
VP-002's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for VP-002. Showing past 6 months and next 12 months · 4 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| VP-002 | PYC Therapeutics | Antisense oligonucleotide | Preclinical | 0 | ||||
| Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease | Neurocrine Biosciences | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada | Neurocrine Biosciences | — | Phase 3 | — | — | — | — | — |
| A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease | Novartis Pharmaceuticals | — | Phase 3 | — | — | — | — | — |
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Vanderbilt University Medical Center | — | PHASE2/PHASE3 | — | — | — | — | — |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease | Skyhawk Therapeutics, Inc. | — | PHASE2/PHASE3 | — | — | — | — | — |
| Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease | Skyhawk Therapeutics, Inc. | — | PHASE2/PHASE3 | — | — | — | — | — |
| An Extension of SKY-0515 in Participants With Huntington's Disease | Skyhawk Therapeutics, Inc. | — | PHASE2/PHASE3 | — | — | — | — | — |
| Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — | Phase 2 | — | — | — | — | — |
| GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease | Hoffmann-La Roche | — | Phase 2 | — | — | — | — | — |
| A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers | Western Sydney Local Health District | — | Phase 2 | — | — | — | — | — |
| The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease | Oslo University Hospital | — | Phase 2 | — | — | — | — | — |
| An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) | Novartis Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. | ExoRNA Bioscience | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD | Vico Therapeutics B. V. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease | Leslie Thompson | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | UniQure Biopharma B.V. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease | UniQure Biopharma B.V. | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease | Hoffmann-La Roche | — | PHASE1/PHASE2 | — | — | — | — | — |